NeuroTherapia Announces EMA Approval of its Phase 2 Trial for the Treatment of Alzheimer’s Disease
Trial Designed to Demonstrate Target Engagement, in addition toStandardSafety and Pharmacokinetics NeuroTherapia, Inc., a clinical-stage company focused on developing oraltherapies for neurodegenerative diseases, announced it has received approval for its Phase 2 clinical trial from the European Medicines Agency (EMA). NTRX-07, the Company's lead molecule, will be administered to Alzheimer's disease (AD) participants for 28 […]